share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K：重大事件
美股SEC公告 ·  08/14 16:08
Moomoo AI 已提取核心訊息
On August 13, 2024, Avalo Therapeutics, Inc. held its annual stockholders meeting where several key proposals were voted upon. The stockholders approved the Fourth Amended and Restated 2016 Equity Incentive Plan, which increases the total number of shares reserved for issuance to 3,548,882, extends the automatic increase in shares through January 1, 2034, and bases the increase on 5% of the outstanding common and Series C Preferred Stock, plus outstanding prefunded warrants as of the end of the previous year. Additionally, the Amended and Restated Employee Stock Purchase Plan was approved, increasing the reserved shares to 234,878 and extending the automatic annual increase with similar terms. The Board had previously approved these plans on June 6, 2024, pending stockholder approval. During the meeting, seven board members were elected to serve until the 2025 Annual Meeting, and the issuance of shares for various purposes including the conversion of Series C Preferred Stock and the exercise of warrants was approved. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
On August 13, 2024, Avalo Therapeutics, Inc. held its annual stockholders meeting where several key proposals were voted upon. The stockholders approved the Fourth Amended and Restated 2016 Equity Incentive Plan, which increases the total number of shares reserved for issuance to 3,548,882, extends the automatic increase in shares through January 1, 2034, and bases the increase on 5% of the outstanding common and Series C Preferred Stock, plus outstanding prefunded warrants as of the end of the previous year. Additionally, the Amended and Restated Employee Stock Purchase Plan was approved, increasing the reserved shares to 234,878 and extending the automatic annual increase with similar terms. The Board had previously approved these plans on June 6, 2024, pending stockholder approval. During the meeting, seven board members were elected to serve until the 2025 Annual Meeting, and the issuance of shares for various purposes including the conversion of Series C Preferred Stock and the exercise of warrants was approved. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
2024年8月13日，Avalo Therapeutics， Inc.召開了其股東年會，就幾項重要議案進行了投票。股東已批准第四次修訂的2016年股權激勵計劃，該計劃將發行股票的總數增加到3,548,882股，於2034年1月1日之前自動增加股票數量，其增長基於上一年末的普通股和C系列優先股募集的5％，並加上由前一年年末通用股和C系列優先股中持有的預先資助的認股權。此外，修改和重訂的員工股票購買計劃已獲批准，將保留的股票增加到234,878股，並按類似條款延長自動年度增加。董事會先前已經在2024年6月6日批准了這些計劃，等待股東批准。 在會議期間，7名董事會成員當選服務於2025年年會，並批准了股份發行，包括轉換C系列優先股和行使認股權。 股東還批准了Ernst＆Young會計師事務所擔任截至2024年12月31日的獨立註冊公共會計師。
2024年8月13日，Avalo Therapeutics， Inc.召開了其股東年會，就幾項重要議案進行了投票。股東已批准第四次修訂的2016年股權激勵計劃，該計劃將發行股票的總數增加到3,548,882股，於2034年1月1日之前自動增加股票數量，其增長基於上一年末的普通股和C系列優先股募集的5％，並加上由前一年年末通用股和C系列優先股中持有的預先資助的認股權。此外，修改和重訂的員工股票購買計劃已獲批准，將保留的股票增加到234,878股，並按類似條款延長自動年度增加。董事會先前已經在2024年6月6日批准了這些計劃，等待股東批准。 在會議期間，7名董事會成員當選服務於2025年年會，並批准了股份發行，包括轉換C系列優先股和行使認股權。 股東還批准了Ernst＆Young會計師事務所擔任截至2024年12月31日的獨立註冊公共會計師。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息